Ernst Lengyel to Metformin
This is a "connection" page, showing publications Ernst Lengyel has written about Metformin.
Connection Strength
1.527
-
Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. 2015 Apr; 212(4):479.e1-479.e10.
Score: 0.398
-
Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 Jan; 119(1):61-7.
Score: 0.328
-
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial. Gynecol Oncol. 2025 Mar; 194:18-24.
Score: 0.204
-
Mesothelial Cell HIF1a Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. Cell Rep. 2019 12 17; 29(12):4086-4098.e6.
Score: 0.142
-
SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019 04; 17(4):870-881.
Score: 0.134
-
Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. Cell Metab. 2016 11 08; 24(5):728-739.
Score: 0.114
-
Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. 2015 Sep 15; 6(27):23548-60.
Score: 0.106
-
Old drug, new trick: repurposing metformin for gynecologic cancers? Gynecol Oncol. 2014 Dec; 135(3):614-21.
Score: 0.100